Lenvatinib plus PD-1 inhibitor improves survival versus bevacizumab plus PD-1 inhibitor in unresectable hepatocellular carcinoma
Meta-analysis shows lenvatinib-based regimens improve survival for unresectable liver cancer in East Asia
This systematic review and meta-analysis evaluated first-line treatment for unresectable hepatocellular carcinoma in East Asian populations.
A meta-analysis of East Asian patients with unresectable liver cancer found lenvatinib-based regimens improved survival compared to bevacizu…
Network meta-analysis finds similar overall survival for three HCC regimens
Three drugs show similar survival for unresectable liver cancer patients
A network meta-analysis of 11 studies in unresectable hepatocellular carcinoma found no statistically significant differences in overall sur…
Three drugs show similar survival for unresectable liver cancer patients, offering patients clearer choices without proving one option is de…
Combination immunotherapy and targeted therapy regimens show favorable survival outcomes versus monotherapies in unresectable hepatocellular carcinoma
New Data Reveals Which Liver Cancer Treatments Work Best Over Time
This systematic review and pooled analysis of parametric survival curves from 15 randomized controlled trials evaluated first-line treatment…
This research shows that combining two different cancer drugs helps patients live longer than using just one, but the benefit isn't constant…
HBV-positive status linked to higher surgical conversion in unresectable HCC receiving triple therapy
HBV-positive linked to better outcomes in liver cancer triple therapy
This single-center retrospective cohort study evaluated triple therapy with TACE, lenvatinib, and PD-1 inhibitors in 190 patients with initi…
In unresectable liver cancer, triple therapy with TACE, lenvatinib, and PD-1 inhibitors worked better in HBV-positive patients, a small retr…
Triple therapy with TACE, TKIs, and ICIs shows survival benefits in unresectable hepatocellular carcinoma
Triple therapy offers a 52% chance of living three years with advanced liver cancer
This retrospective cohort study evaluated 270 patients with unresectable hepatocellular carcinoma receiving first-line triple therapy across…
Patients with advanced liver cancer receiving triple therapy had a 52% chance of surviving three years, offering new hope for those facing d…
TACE plus donafenib and camrelizumab shows improved outcomes in unresectable hepatocellular carcinoma
Liver Cancer Patients May Live Twice as Long With New Combo
This single-center retrospective cohort study compared TACE plus donafenib and camrelizumab to TACE plus donafenib alone in 116 patients wit…
A new combination therapy could nearly double survival time for advanced liver cancer patients.
TACE plus camrelizumab and rivoceranib prolongs progression-free survival versus TACE alone in unresectable HCC
Combination therapy extends time without cancer progression in liver cancer patients
This phase II randomized trial in 200 patients with unresectable hepatocellular carcinoma compared TACE plus camrelizumab and rivoceranib (T…
Adding two new drugs to standard liver cancer treatment helped patients go 10.8 months longer without their cancer getting worse compared to…
Research across Hepatocellular Carcinoma
Related studies from across the Hepatocellular Carcinoma family.
Immune-based combinations show superior overall survival compared to sorafenib in advanced hepatocellular carcinoma
New data shows better survival for liver cancer patients
This systematic review and network meta-analysis of 8,138 patients evaluated immune-based combinations versus monotherapies for advanced hep…
New research highlights how specific immune-based drug combinations can improve survival rates for people with advanced liver cancer.
OTUD7B acts as a context-dependent regulator in various cancers and inflammatory conditions
Protein OTUD7B plays complex roles in cancer and heart health
This systematic review examines the molecular roles of OTUD7B across multiple malignancies and inflammatory models. The findings indicate th…
A protein called OTUD7B acts as a double-edged sword, helping some conditions while fueling the growth of others.
Combining Pentraxin-3 and AFP increases sensitivity to 0.92 for hepatocellular carcinoma diagnosis in chronic liver disease
New blood test helps doctors find liver cancer earlier with better accuracy than old methods alone
This systematic review and meta-analysis evaluated diagnostic markers in adults with chronic liver disease suspected of hepatocellular carci…
A review of 1,179 patients shows a new marker called PTX3 works well for finding liver cancer. Using both PTX3 and AFP together finds more c…
Narrative review on KMT2C alterations in gastrointestinal cancers and therapeutic implications
Genetic changes in gut cancers may open new treatment doors for patients
This narrative review synthesizes evidence on KMT2C alterations across gastrointestinal malignancies. It links KMT2C dysfunction to transcri…
A review of genetic changes in gastrointestinal cancers suggests new ways to treat tumors by targeting specific DNA repair weaknesses.
Review of antiviral and immunotherapeutic strategies for chronic hepatitis B
New antiviral strategies show promise for chronic hepatitis B infection
This narrative review synthesizes evidence on antiviral and immunotherapeutic strategies for chronic hepatitis B. The authors highlight func…
A review of new treatments suggests combination therapies may offer future value for managing chronic hepatitis B, cirrhosis, and liver canc…
FDA approves OPDIVO QVANTIG for multiple advanced cancer indications including renal cell carcinoma and melanoma
FDA approves subcutaneous nivolumab combination for multiple advanced cancers
This FDA approval document grants authorization for OPDIVO QVANTIG, a subcutaneous combination of nivolumab and hyaluronidase, for specified…
The FDA has approved a new subcutaneous form of nivolumab for several advanced cancers, offering a more convenient treatment option for elig…
Bayesian network meta-analysis of first-line immunotherapy versus TKI for advanced hepatocellular carcinoma
Immunotherapy Outperforms Standard Care for Advanced Liver Cancer
This Bayesian network meta-analysis of 7,301 patients with advanced hepatocellular carcinoma synthesized evidence from randomized trials. It…
A new analysis of 10 clinical trials shows that immunotherapy drugs help people with advanced liver cancer live longer than standard treatme…
Narrative review on hepatocellular carcinoma highlights translational gaps and heterogeneity
Liver Cancer Secretly Uses Acid to Grow Stronger Inside You
This narrative review synthesizes challenges in hepatocellular carcinoma research. It notes considerable gaps between preclinical findings a…
• Lactate isn't waste but fuels liver cancer growth • Future patients could get better treatments • Still in lab testing
Meta-analysis links high monocyte-to-lymphocyte ratio to poor survival in hepatocellular carcinoma
A simple blood test may predict liver cancer survival
This meta-analysis of 7113 patients with hepatocellular carcinoma found that a high monocyte-to-lymphocyte ratio (MLR) is significantly asso…
A routine blood test called the monocyte-to-lymphocyte ratio may predict survival in liver cancer patients.
Systematic review and meta-analysis shows worse liver transplant survival for Black patients compared to White patients
Black patients faced worse survival rates after liver transplant compared to White patients in this review
This systematic review and meta-analysis evaluated overall patient and graft survival after liver transplant across diverse ethnic populatio…
A large review of twelve studies found Black patients had lower survival rates after liver transplants than White patients. Asian and Hispan…
Early time-of-day immune checkpoint inhibitor administration improves overall survival in advanced solid tumors
Cancer Patients Live Longer When Immunotherapy Starts Early in Day
This systematic review and meta-analysis evaluated 6129 patients with advanced solid tumors receiving immune checkpoint inhibitors. Earlier …
• Morning immunotherapy shots link to longer survival for advanced cancers • Helps patients fighting lung stomach kidney and other tough can…
Meta-analysis shows improved survival with PD-1/PD-L1 inhibitor plus bevacizumab versus sorafenib in advanced HCC
New Drug Combo Outperforms Standard Care for Liver Cancer
This meta-analysis evaluated PD-1/PD-L1 inhibitor plus bevacizumab versus sorafenib in treatment-naive individuals with advanced hepatocellu…
A powerful two-drug combination cuts the risk of death by 35 percent compared to the standard treatment for people with advanced liver cance…
Questions about Unresectable Hepatocellular Carcinoma
Does adding camrelizumab improve outcomes for unresectable hepatocellular carcinoma patients?
Adding camrelizumab to standard treatments like TACE and targeted drugs significantly improves tumor response, disease control, and survival times for patients with unresectable hepatocellular carcinoma.
Full answer →Can triple therapy help patients with unresectable hepatocellular carcinoma live longer?
Yes, triple therapy (TACE plus targeted drugs and immunotherapy) can help patients with unresectable hepatocellular carcinoma live longer, with studies showing improved overall survival and progression-free survival compared to TACE alone or double therapy.
Full answer →Does having HBV make surgery more likely for unresectable hepatocellular carcinoma?
Having hepatitis B virus (HBV) infection is linked to a higher chance of surgical conversion for patients with unresectable hepatocellular carcinoma treated with triple therapy.
Full answer →